Evaluation of expression based markers for the detection of breast cancer cells
- 1 December 2005
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 97 (1), 41-47
- https://doi.org/10.1007/s10549-005-9085-8
Abstract
Genes that are expressed in a highly tissue- or disease-specific manner provide possible targets for therapeutics, early detection of cancer, and monitoring of disease burden during and after treatment. Further, genes of this type that code for secreted or shed proteins may allow for serum detection of the product facilitating our ability to specifically detect the cancer in all circumstances. To this end, we are working towards identification and characterization of such genes that are specifically expressed in breast epithelium. In the current study, we have measured the expression of two markers that emerged from a screen of the Incyte LifeSeq Database and were subsequently shown to be highly restricted to breast epithelium termed BU101 (also called Lipophilin B) and BS106 (small mucin-like protein). These two novel markers were compared with two other candidate markers, Mammaglobin and Cytokeratin 19 (CK19). Utilizing quantitative real-time PCR, we compared the expression of these four genes in a series of 95 primary breast cancers, 9 lymph nodes from breast cancer patients, 13 lymph nodes from non-cancer patients and 10 normal breast tissues. Cytokeratin was shown to be highly sensitive in detecting all breast cancers, while BU101, BS106 and Mammaglobin were more restricted. While no one of the these markers efficiently detects all breast cancers, a combination of two or more could achieve a very high sensitivity in assaying for circulating or occult breast cancer cells.Keywords
This publication has 21 references indexed in Scilit:
- Early distant relapse in ?node-negative? breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumourThe Journal of Pathology, 2001
- Prognostic Significance of Occult Bone Marrow Micrometastases of Breast Cancer Detected by Quantitative Polymerase Chain Reaction for Cytokeratin 19 mRNAJapanese Journal of Cancer Research, 2000
- Mammaglobin Gene Expression: A Superior Marker of Breast Cancer Cells in Peripheral Blood in Comparison to Epidermal-Growth-Factor Receptor and Cytokeratin-19Laboratory Investigation, 2000
- Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II, or III Breast CancerNew England Journal of Medicine, 2000
- Lipophilins: Human Peptides Homologous to Rat ProstateinBiochemical and Biophysical Research Communications, 1999
- Microstaging of Breast Cancer Patients Using Cytokeratin Staining of the Sentinel Lymph NodeAnnals of Surgical Oncology, 1999
- Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patientsBone Marrow Transplantation, 1997
- Genetic basis for p53 overexpression in human breast cancer.Proceedings of the National Academy of Sciences, 1991
- Inhibition of phagocyte chemotaxis by uteroglobin, an inhibitor of blastocyst rejectionBiochemical Pharmacology, 1988
- Uteroglobin inhibits phospholipase A2 activityLife Sciences, 1986